CA3026743C - Microparticles comprising a sulphur-containing compound - Google Patents

Microparticles comprising a sulphur-containing compound Download PDF

Info

Publication number
CA3026743C
CA3026743C CA3026743A CA3026743A CA3026743C CA 3026743 C CA3026743 C CA 3026743C CA 3026743 A CA3026743 A CA 3026743A CA 3026743 A CA3026743 A CA 3026743A CA 3026743 C CA3026743 C CA 3026743C
Authority
CA
Canada
Prior art keywords
microparticles
cysteamine
agent
stabilizing agent
particle size
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3026743A
Other languages
English (en)
French (fr)
Other versions
CA3026743A1 (en
Inventor
Deborah O'neil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NovaBiotics Ltd
Original Assignee
NovaBiotics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NovaBiotics Ltd filed Critical NovaBiotics Ltd
Priority to CA3096121A priority Critical patent/CA3096121C/en
Publication of CA3026743A1 publication Critical patent/CA3026743A1/en
Application granted granted Critical
Publication of CA3026743C publication Critical patent/CA3026743C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Pigments, Carbon Blacks, Or Wood Stains (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Accessories For Mixers (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA3026743A 2016-06-07 2017-06-06 Microparticles comprising a sulphur-containing compound Active CA3026743C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3096121A CA3096121C (en) 2016-06-07 2017-06-06 Smart microfluidie mixing instrument and cartridges

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662346969P 2016-06-07 2016-06-07
US62/346,969 2016-06-07
GB1609940.0 2016-06-07
GBGB1609940.0A GB201609940D0 (en) 2016-06-07 2016-06-07 Microparticles
PCT/GB2017/051637 WO2017212249A1 (en) 2016-06-07 2017-06-06 Microparticles comprising a sulphur-containing compound

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3096121A Division CA3096121C (en) 2016-06-07 2017-06-06 Smart microfluidie mixing instrument and cartridges

Publications (2)

Publication Number Publication Date
CA3026743A1 CA3026743A1 (en) 2017-12-14
CA3026743C true CA3026743C (en) 2024-05-28

Family

ID=56508202

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3026743A Active CA3026743C (en) 2016-06-07 2017-06-06 Microparticles comprising a sulphur-containing compound
CA3096121A Active CA3096121C (en) 2016-06-07 2017-06-06 Smart microfluidie mixing instrument and cartridges

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3096121A Active CA3096121C (en) 2016-06-07 2017-06-06 Smart microfluidie mixing instrument and cartridges

Country Status (16)

Country Link
US (1) US11369568B2 (enExample)
EP (1) EP3463325B1 (enExample)
JP (1) JP7195934B2 (enExample)
KR (1) KR102412212B1 (enExample)
CN (1) CN109310654A (enExample)
AU (1) AU2017277897B2 (enExample)
BR (1) BR112018075221B1 (enExample)
CA (2) CA3026743C (enExample)
DK (1) DK3463325T3 (enExample)
ES (1) ES2965017T3 (enExample)
FI (1) FI3463325T3 (enExample)
GB (1) GB201609940D0 (enExample)
MX (1) MX2018014278A (enExample)
SG (1) SG11201810934TA (enExample)
WO (1) WO2017212249A1 (enExample)
ZA (1) ZA201807852B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10905660B2 (en) 2016-06-07 2021-02-02 Novabiotics Limited Microparticles
EP3572068A1 (en) * 2018-05-22 2019-11-27 RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. New salt of cysteamine for the preparation of highly respirable particles
WO2020079186A1 (en) * 2018-10-17 2020-04-23 Novabiotics Limited Dosage regime
JP2023540985A (ja) * 2020-09-03 2023-09-27 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム 噴霧乾燥低吸湿性活性粉末組成物
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
CN118871100A (zh) * 2021-12-07 2024-10-29 西拉治疗公司 抗病毒治疗剂及其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8901570D0 (sv) * 1989-05-02 1989-05-02 Draco Ab Organic salts of cysteine derivatives
CN101094651B (zh) 2004-12-30 2011-03-09 多贝尔有限公司 含有胶原凝集素家族蛋白质或者其变体的喷雾干燥的组合物和其制备方法
AR057623A1 (es) 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
JP5315252B2 (ja) 2006-12-22 2013-10-16 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ 眼科用薬物の輸送に有用なゲル
CN101342155B (zh) * 2007-07-11 2012-01-04 天津帝士力投资控股集团有限公司 一种(r,r)-福莫特罗吸入粉雾剂及其制备方法
EP2370053A1 (de) * 2008-11-27 2011-10-05 Boehringer Ingelheim International GmbH Neue pulverförmige kristalline arzneimittel zur inhalation
CN102341105B (zh) 2009-02-03 2014-09-17 微生物公司 用作上皮组织、急性和慢性伤口、细菌生物被膜和其他适应症的抗菌剂的铋硫醇
WO2010138419A2 (en) 2009-05-23 2010-12-02 Obio Pharmaceutical (H.K.) Ltd. Materials and methods for treating viral infections
GB201021186D0 (en) * 2010-12-14 2011-01-26 Novabiotics Ltd Composition
CN103717231B (zh) 2011-05-19 2016-08-17 萨瓦拉股份有限公司 干粉万古霉素组合物以及相关方法
JP5981123B2 (ja) 2011-10-11 2016-08-31 サンサ コーポレーション （バルバドス） インク ニコチン薬の製造法およびその方法により製造される医薬
US9468612B2 (en) * 2011-10-26 2016-10-18 Seattle Children's Hospital Cysteamine in the treatment of fibrotic disease
US9493775B2 (en) * 2012-02-10 2016-11-15 Whitehead Institute For Biomedical Research Inhibition of the glycine cleavage system for treatment of cancer
ITMI20130572A1 (it) * 2013-04-10 2014-10-11 Eratech Srl Composizione comprendente almeno due polveri secche ottenute per spray dry per aumentare la stabilita' della formulazione
JP6483714B2 (ja) * 2013-10-11 2019-03-13 ローレンス エス． ジスマン， 噴霧乾燥製剤
GB201416716D0 (en) 2014-09-22 2014-11-05 Novabiotics Ltd Use
ITUA20161799A1 (it) * 2016-03-18 2017-09-18 Recordati Ind Chimica E Farmaceutica S P A Composizione farmaceutica a rilascio prolungato comprendente cisteamina o un suo sale
US10905660B2 (en) * 2016-06-07 2021-02-02 Novabiotics Limited Microparticles

Also Published As

Publication number Publication date
BR112018075221B1 (pt) 2024-02-06
CA3096121C (en) 2022-11-15
JP2019517541A (ja) 2019-06-24
CA3096121A1 (en) 2017-12-14
SG11201810934TA (en) 2019-01-30
RU2018142841A3 (enExample) 2020-09-30
CA3026743A1 (en) 2017-12-14
KR102412212B1 (ko) 2022-06-23
JP7195934B2 (ja) 2022-12-26
EP3463325B1 (en) 2023-11-08
NZ748596A (en) 2025-06-27
ES2965017T3 (es) 2024-04-10
AU2017277897B2 (en) 2022-09-08
ZA201807852B (en) 2023-05-31
AU2017277897A1 (en) 2018-12-20
US20190175501A1 (en) 2019-06-13
FI3463325T3 (fi) 2023-12-19
GB201609940D0 (en) 2016-07-20
DK3463325T3 (da) 2024-01-02
EP3463325A1 (en) 2019-04-10
BR112018075221A2 (pt) 2019-03-19
US11369568B2 (en) 2022-06-28
MX2018014278A (es) 2019-03-14
RU2018142841A (ru) 2020-06-04
CN109310654A (zh) 2019-02-05
WO2017212249A1 (en) 2017-12-14
KR20190016957A (ko) 2019-02-19

Similar Documents

Publication Publication Date Title
CA3026743C (en) Microparticles comprising a sulphur-containing compound
US10905660B2 (en) Microparticles
ES2899621T3 (es) Polvos secos catiónicos que comprenden sal de magnesio
JP6392422B2 (ja) 吸入用の一価金属カチオン乾燥粉末
CA2981038C (en) Dry powder vancomycin compositions and associated methods
US9539233B2 (en) Gallium formulation for the treatment and prevention of infectious diseases
RS52239B (sr) Farmaceutske formulacije i metode za tretman infekcija respiratornog trakta
JP2012522009A (ja) 肺炎および人工呼吸器関連気管気管支炎を治療および予防するための方法
CA2809666A1 (en) Dry powder formulations and methods for treating pulmonary diseases
Manniello et al. Clarithromycin and N-acetylcysteine co-spray-dried powders for pulmonary drug delivery: A focus on drug solubility
CN102448439A (zh) 用于改变黏膜内衬的生物物理特性的柠檬酸钙及乳酸钙调配物
PT1594500E (pt) Tratamento para doenças bacterianas dos órgãos respiratórios por aplicação local de fluoroquinolonas
RU2780397C2 (ru) Микрочастицы, содержащие серосодержащие соединения
US20240397944A1 (en) Methods for biofilm disruption
ES2918193T3 (es) Polvo medicamentoso para administración por inhalación y un proceso del mismo
IL263540B2 (en) Microparticles that include a sulfur-containing compound

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220525

EEER Examination request

Effective date: 20220525

EEER Examination request

Effective date: 20220525

EEER Examination request

Effective date: 20220525

EEER Examination request

Effective date: 20220525

EEER Examination request

Effective date: 20220525

EEER Examination request

Effective date: 20220525

EEER Examination request

Effective date: 20220525